海通证券晨报-20251204

Financial Engineering Research - The Q4 style rotation model indicates signals for small-cap and growth stocks, with recommended sectors including power equipment and renewable energy [2][4] - The dual-driven rotation strategy for Q4 yields a composite score of -1, predicting a preference for small-cap stocks [4] - The value-growth rotation strategy for Q4 shows a composite score of -3, indicating a preference for growth stocks [4] Biopharmaceutical Research - Continuous recommendation for innovative drugs and medical devices along the industry chain [5][6] - Maintain "overweight" ratings for A-share stocks such as Heng Rui Medicine, Ke Lun Pharmaceutical, and others, included in the December monthly portfolio [6][7] - The biopharmaceutical sector underperformed the broader market in November, with a decline of 3.6% compared to a 1.7% drop in the Shanghai Composite Index [7][8] Industry Rotation Insights - In November, the composite factor strategy yielded an excess return of -0.58%, while the single-factor strategy showed an excess return of -0.83% [4] - For December, recommended sectors for the single-factor strategy include banking, construction, non-bank financials, and power equipment [4] - The composite factor strategy recommends sectors such as telecommunications, comprehensive finance, and public utilities [4] Consumer Electronics - The launch of the AI phone assistant by Doubao signifies the upcoming era of AI smartphones, enhancing the hardware ecosystem [20][21] - Doubao's AI assistant can execute complex commands and integrate deeply with operating systems, providing a seamless user experience [21][22] - The assistant's capabilities include cross-application tasks, enhancing user interaction with various platforms [21][22] Medical Commercial Sector - The report maintains an "overweight" rating for leading chain pharmacies, anticipating recovery driven by supply-side clearing and demand-side recovery [15][16] - The retail scale of China's physical pharmacies is projected to reach 611.9 billion yuan in 2024, despite a decline of 1.8% year-on-year [16][17] - The report highlights a recovery trend in drug sales, particularly in essential medicines, amidst a challenging consumer environment [17][18] New Materials Sector - The company achieved a revenue growth of 2.31% year-on-year in the first three quarters of 2025, driven by new materials [27][28] - The company is actively expanding its new materials business, with significant projects underway [28] - The controlling shareholder plans to increase its stake in the company, reflecting confidence in future growth prospects [27][28]